Roche Unveils NVIDIA-Powered AI Factory for Therapeutics and Diagnostics
- Roche adds 2,176 NVIDIA GPUs, totaling over 3,500, for its AI infrastructure.
- The NVIDIA collaboration began in 2023, enhancing drug development with AI.
- Roche's AI factory supports R&D, manufacturing, and diagnostics with advanced computing.
- Roche aims for net zero by 2045 through the Science Based Targets initiative.
AI Infrastructure Expansion
Roche has expanded its AI infrastructure by adding 2,176 NVIDIA Blackwell GPUs, bringing its total to over 3,500 GPUs. This makes it the largest announced hybrid-cloud AI factory in the pharmaceutical industry.
Strategic NVIDIA Collaboration
The expansion marks a new phase in Roche's collaboration with NVIDIA, which began in 2023. The partnership leverages NVIDIA's AI infrastructure to accelerate drug development through high-quality data and innovative AI applications.
Applications Across Value Chain
Roche's AI factory integrates advanced computing across its entire value chain, from R&D to manufacturing and diagnostics. In R&D, the NVIDIA BioNeMo platform enhances Roche's Lab-in-the-Loop, connecting experiments with AI models to accelerate discoveries. In manufacturing, digital twins powered by NVIDIA Omniverse optimize processes and designs. In diagnostics, NVIDIA Parabricks software enables insights from vast datasets.
Commitment to Sustainability
Roche is committed to achieving net zero by 2045, aligning with the Science Based Targets initiative and the Sustainable Markets Initiative. This commitment underscores the company's focus on integrating sustainability with technological advancements.
Source: Roche